Karus Therapeutics, a leader in the development of innovative medicines for the treatment of inflammatory disease and cancer, has announced that it will be giving two poster presentations at the AACR Annual Meeting in Philadelphia, 18–22 April 2015.
Stephen Shuttleworth, Karus’s CSO, will present the posters describing the company’s pre-clinical cancer programmes. The title of the posters are ‘Design and development of a novel series of orally active, selective PI3K-p110β/δ inhibitors for the treatment of solid and hematological cancers’ and ‘Design and development of a novel series of HDAC6-selective inhibitors for the treatment of hematological and solid tumors’.
The presentations will take place from 8am to 12pm on Tuesday 21 April 2015 in Section 34.
Simon Kerry, Karus Therapeutics’ CEO will also be attending the conference.
For more information on Karus’s presentations or for media enquiries, please contact email@example.com.